Cancer Immunotherapy Trials Network

Facilitating Early Phase Trials

About Us

CITN facilitates the broad availability of immunotherapy agents with known and proven biologic function for treating cancer patients. Our efforts employs the collective expertise of top academic immunologists from  multiple organizations. 

Prioritizing Promising Agents

Our Science

Building on NCI prioritization workshops, we focus on conducting early phase clinical trials that use agents and novel regimens with consensus prioritization that are most likely to prove effective and lead to regulatory approval in the foreseeable future.

Developing Innovative Drugs

Partnerhips

We align the scientific, clinical and management resources of CITN and biopharmaceutical partners to create unique synergy to advance promising immunotherapy compounds to the clinic more quickly, efficiently and cost effectively.